LRMR Stock Price, Larimar Therapeutics, . Quote, Chart

Market Summary

USD7.39-0.04

Delayed

-0.54%

LRMR Stock Price

View Fullscreen

LRMR RSI Chart

LRMR Valuation

Market Cap

471.5M

Price/Earnings (Trailing)

-10.45

Price/Sales (Trailing)

222.35

Price/Free Cashflow

-12.92

LRMR Price/Sales (Trailing)

LRMR Profitability

Return on Equity

-19.55%

Return on Assets

-18.18%

Free Cashflow Yield

-7.74%

LRMR Fundamentals

LRMR Revenue

Revenue (TTM)

2.3M

LRMR Earnings

Earnings (TTM)

-45.1M

Earnings Growth (Yr)

-125.25%

Earnings Growth (Qtr)

-13.14%

Breaking Down LRMR Revenue

Last 7 days

3.8%

Last 30 days

4.8%

Last 90 days

-42.2%

Trailing 12 Months

96.0%

How does LRMR drawdown profile look like?

LRMR Financial Health

Current Ratio

17.99

LRMR Investor Care

Shares Dilution (1Y)

47.45%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	2.3M	0	0	0
2018	1.0M	1.1M	1.5M	1.9M
2017	912.0K	934.0K	970.0K	996.0K
2016	608.0K	770.0K	857.0K	894.0K
2015	130.5K	233.0K	335.5K	438.0K
2014	0	0	0	28.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Larimar Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	flynn james e	bought	12,500,000	8.74	1,430,200	-
Feb 16, 2024	flynn james e	bought	12,500,000	8.74	1,430,210	-
Feb 14, 2024	thomas frank e	bought	22,000	11.00	2,000	-
Jan 17, 2024	shankar gopi	acquired	-	-	22,500	chief development officer
Jan 17, 2024	clayton russell	acquired	-	-	22,500	chief medical officer
Jan 17, 2024	ben-maimon carole	acquired	-	-	66,125	president and ceo
Jan 17, 2024	celano michael	acquired	-	-	31,250	chief financial officer
Dec 07, 2023	shankar gopi	bought	18,661	3.7323	5,000	chief development officer
May 17, 2023	ben-maimon carole	bought	18,525	3.705	5,000	president and ceo

Which funds bought or sold LRMR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	294,681	294,681	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.00	657	19,863	-%
May 16, 2024	COMERICA BANK	new	-	3,150	3,150	-%
May 15, 2024	NOMURA HOLDINGS INC	new	-	160,468	160,468	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	757,391	757,391	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	new	-	45,884,200	45,884,200	0.59%
May 15, 2024	DAFNA Capital Management LLC	added	102	3,508,250	4,981,870	1.13%
May 15, 2024	Voya Investment Management LLC	added	1,048	947,492	999,694	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2,452	25,330,500	25,939,600	-%
May 15, 2024	Royal Bank of Canada	reduced	-93.25	-36,000	4,000	-%

Are Funds Buying or Selling LRMR?

Are funds buying LRMR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LRMR

No. of Funds

Unveiling Larimar Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	flynn james e	9.64%	6,151,389	SC 13D/A
Feb 26, 2024	ra capital management, l.p.	9.5%	6,045,351	SC 13G
Feb 16, 2024	flynn james e	10.07%	6,151,389	SC 13D/A
Feb 15, 2024	flynn james e	10.75%	4,721,183	SC 13D/A
Feb 14, 2024	blue owl capital holdings lp	7.78%	3,414,468	SC 13G
Feb 14, 2024	verition fund management llc	6.4%	2,811,131	SC 13G
Feb 14, 2024	perceptive advisors llc	0%	0	SC 13G/A
Feb 13, 2024	janus henderson group plc	6.0%	2,641,065	SC 13G/A
Aug 18, 2023	janus henderson group plc	5.1%	2,191,411	SC 13G
Mar 17, 2023	flynn james e	10.91%	4,721,183	SC 13D/A

Recent SEC filings of Larimar Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	S-3	S-3
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 12, 2024	PRE 14A	PRE 14A
Mar 15, 2024	SC 13D/A	13D - Major Acquisition
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Larimar Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Larimar Therapeutics, Inc. News

Latest updates

Larimar Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2
Revenue	-4.9%	642	675	623	324	267	256	266	247	227	230	230	225	209	193	143	63.00	39.00	26.00	14.00	1.00
Operating Expenses	-9.6%	13,277	14,691	15,169	15,560	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	12.7%	3,646	3,234	3,339	3,351	3,269	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-15.9%	9,631	11,457	11,830	12,209	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	0.1%	-61.27*	-61.31*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.2%	500	499	475	466	458	8.00	31.00	53.00	73.00	97.00	132	140	160	180	200	213	213	212	213	443
EBT Margin	0%	-63.27*	-63.27*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	67.6%	-4,724	-14,570	-15,067	-15,775	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	158.7%	248	96.00	104	112	119	126	133	63.00	71.00	79.00	88.00	81.00	93.00	105	114	125	74.00	83.00	93.00	104	110
Current Assets	156.1%	231	90.00	98.00	106	113	121	127	57.00	65.00	72.00	81.00	74.00	86.00	98.00	108	119	65.00	5.00	83.00	94.00	107
Cash Equivalents	311.7%	110	27.00	39.00	94.00	112	27.00	86.00	20.00	63.00	70.00	72.00	71.00	62.00	68.00	101	113	39.00	1.00	43.00	37.00	36.00
Net PPE	-11.7%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	0.00
Liabilities	22.1%	17.00	14.00	11.00	12.00	13.00	16.00	14.00	13.00	14.00	14.00	16.00	13.00	14.00	15.00	11.00	13.00	23.00	6.00	33.00	32.00	28.00
Current Liabilities	35.1%	13.00	10.00	7.00	7.00	8.00	11.00	9.00	8.00	9.00	9.00	10.00	8.00	8.00	9.00	5.00	7.00	10.00	6.00	16.00	13.00	14.00
Shareholder's Equity	182.5%	231	82.00	93.00	100	106	111	119	50.00	57.00	64.00	72.00	68.00	79.00	90.00	103	113	2.00	54.00	2.00	1.00	1.00
Retained Earnings	-7.7%	-203	-188	-175	-166	-158	-151	-142	-133	-125	-116	-107	-90.30	-77.70	-65.61	-51.41	-41.14	-399	-23.13	-389	-376	-364
Additional Paid-In Capital	60.7%	434	270	268	266	264	262	261	184	182	181	179	158	156	155	154	154	451	22.00	449	448	446
Shares Outstanding	45.3%	64.00	44.00	44.00	43.00	43.00	43.00	22.00	18.00	18.00	18.00	18.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	80,219	-	-	-	21.00	-	-	-	94.00	-	-	-	123	-	-	-	40.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-11.4%	-10,411	-9,343	-9,200	-7,365	-7,551	-6,672	-5,878	-7,486	-7,533	-7,918	-12,199	-10,782	-11,206	-9,857	-11,222	-12,199	-8,921	-7,911	-5,823	3,506	-12,471
Share Based Compensation	10.9%	2,128	1,918	1,821	2,043	1,833	1,643	1,666	1,675	1,635	1,480	1,463	1,350	1,180	1,010	696	100	29.00	29.00	-1,021	100	2,076
Cashflow From Investing	-2500.4%	-68,364	-2,629	-46,430	-9,838	92,250	-52,234	-3,384	-	-	6,490	-6,791	19,219	5,251	-23,545	-8.00	41,421	-778	-50.00	-	-840	807
Cashflow From Financing	-	162,151	-	-	-	-	-316	-	-	-	-	-	-	-	242	-135	83,903	9,577	3,455	9,950	5,895	95.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LRMR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 12,939	$ 4,562
General and administrative	3,795	3,075
Total operating expenses	16,734	7,637
Loss from operations	(16,734)	(7,637)
Other income net	2,080	1,111
Net loss	$ (14,654)	$ (6,526)
Net loss per share, basic	$ (0.27)	$ (0.15)
Net loss per share, diluted	$ (0.27)	$ (0.15)
Weighted average common shares outstanding, basic	53,553,707	43,897,603
Weighted average common shares outstanding, diluted	53,553,707	43,897,603
Comprehensive loss:
Net loss	$ (14,654)	$ (6,526)
Other comprehensive gain (loss):
Unrealized gain (loss) on marketable securities	(106)	31
Total other comprehensive gain (loss)	(106)	31
Total comprehensive loss	$ (14,760)	$ (6,495)

LRMR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 110,125	$ 26,749
Short-term marketable securities	117,171	60,041
Prepaid expenses and other current assets	3,657	3,385
Total current assets	230,953	90,175
Long-term marketable securities	11,711
Property and equipment, net	604	684
Operating lease right-of-use assets	2,920	3,078
Restricted cash	1,339	1,339
Other assets	678	659
Total assets	248,205	95,935
Current liabilities:
Accounts payable	1,918	1,283
Accrued expenses	10,098	7,386
Operating lease liabilities, current	825	837
Total current liabilities	12,841	9,506
Operating lease liabilities	4,520	4,709
Total liabilities	17,361	14,215
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 63,800,017 and 43,909,069 shares issued and outstanding as of March 31, 2024 and December 31, 2023	64	43
Additional paid-in capital	434,013	270,150
Accumulated deficit	(203,208)	(188,554)
Accumulated other comprehensive gain (loss)	(25)	81
Total stockholders’ equity	230,844	81,720
Total liabilities and stockholders’ equity	$ 248,205	$ 95,935

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

CEO	Dr. Carole S. Ben-Maimon M.D.
WEBSITE	larimartx.com
INDUSTRY	Biotechnology
EMPLOYEES	26

Larimar Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Larimar Therapeutics, Inc.? What does LRMR stand for in stocks?

LRMR is the stock ticker symbol of Larimar Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Larimar Therapeutics, Inc. (LRMR)?

As of Fri May 17 2024, market cap of Larimar Therapeutics, Inc. is 471.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers.

What is the fair value of LRMR stock?

You can check LRMR's fair value in chart for subscribers. The fair value of Larimar Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Larimar Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LRMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Larimar Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether LRMR is over valued or under valued. Whether Larimar Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Larimar Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LRMR.

What is Larimar Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LRMR's PE ratio (Price to Earnings) is -10.45 and Price to Sales (PS) ratio is 222.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LRMR PE ratio will change depending on the future growth rate expectations of investors.